相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study
Lisa Pleyer et al.
LANCET HAEMATOLOGY (2021)
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes
Aziz Nazha et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial
Raphael Itzykson et al.
BLOOD (2020)
Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Michael R. Savona et al.
BLOOD (2020)
Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML
Sandrine Niyongere et al.
LEUKEMIA (2019)
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia
Nolwenn Lucas et al.
LEUKEMIA (2019)
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
Peter Valent et al.
HAEMATOLOGICA (2019)
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
Michael R. Savona et al.
LANCET HAEMATOLOGY (2019)
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
V. Santini et al.
LEUKEMIA (2018)
The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms
Manja Meggendorfer et al.
HAEMATOLOGICA (2018)
The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms
Manja Meggendorfer et al.
HAEMATOLOGICA (2018)
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
Rami Komrokji et al.
LANCET HAEMATOLOGY (2018)
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
Matthieu Duchmann et al.
EBIOMEDICINE (2018)
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
Lucia Masarova et al.
BLOOD (2018)
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable
Prithviraj Bose et al.
BLOOD (2018)
A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset
Dorothee Selimoglu-Buet et al.
NATURE COMMUNICATIONS (2018)
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults Recommendations From the European Hematology Association and the European LeukemiaNet
Raphael Itzykson et al.
HEMASPHERE (2018)
Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Kim-Hien Dao et al.
BLOOD (2018)
Lenalidomide Is Effective Treatment Option for Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis
Megan Melody et al.
BLOOD (2018)
Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis
Kiran Naqvi et al.
BLOOD (2018)
Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories
Sanam Loghavi et al.
BLOOD ADVANCES (2018)
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms
Rita Assi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
Maura Nicolosi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas et al.
HAEMATOLOGICA (2017)
Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2
Silvan Francke et al.
LEUKEMIA & LYMPHOMA (2017)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas et al.
HAEMATOLOGICA (2017)
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
Esther N. Oliva et al.
LANCET HAEMATOLOGY (2017)
Turning the tide in myelodysplastic/myeloproliferative neoplasms
Michael W. N. Deininger et al.
NATURE REVIEWS CANCER (2017)
Monocytosis in polycythemia vera: Clinical and molecular correlates
Daniela Barraco et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
Theo de Witte et al.
BLOOD (2017)
Age-related mutations and chronic myelomonocytic leukemia
C. C. Mason et al.
LEUKEMIA (2016)
Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
Chiara Elena et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
Eric Padron et al.
CLINICAL CANCER RESEARCH (2016)
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale
Hanadi Ramadan et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis
M. M. Patnaik et al.
LEUKEMIA (2016)
A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia
Srinivas K. Tantravahi et al.
LEUKEMIA & LYMPHOMA (2016)
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
Jane Merlevede et al.
NATURE COMMUNICATIONS (2016)
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia
Dorothee Selimoglu-Buet et al.
BLOOD (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
Michael R. Savona et al.
BLOOD (2015)
Treatment of Chronic Myelogenous Leukemia by Blocking Cytokine Alterations Found in Normal Stem and Progenitor Cells
Robert S. Welner et al.
CANCER CELL (2015)
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia
Kristen Meldi et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands
Avinash G. Dinmohamed et al.
LEUKEMIA RESEARCH (2015)
Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications
Leonardo Boiocchi et al.
MODERN PATHOLOGY (2015)
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies
E. Padron et al.
BLOOD CANCER JOURNAL (2015)
Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study
Emnet A. Wassie et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Recombinant human interleukin-10 in patients with chronic myelomonocytic leukemia
Sophie Poechlauer et al.
ANNALS OF HEMATOLOGY (2014)
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms
Sa A. Wang et al.
BLOOD (2014)
Results of a Randomized, Double-Blind Study of Romiplostim Versus Placebo in Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome and Thrombocytopenia
Aristoteles Giagounidis et al.
CANCER (2014)
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia
Manja Meggendorfer et al.
HAEMATOLOGICA (2014)
A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia
M. W. Drummond et al.
LEUKEMIA (2014)
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients
M. M. Patnaik et al.
LEUKEMIA (2014)
Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias
E. Schuler et al.
LEUKEMIA RESEARCH (2014)
The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment
Jason Gotlib et al.
BLOOD (2013)
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
Eric Padron et al.
BLOOD (2013)
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia
Esperanza Such et al.
BLOOD (2013)
Clonal architecture of chronic myelomonocytic leukemias
Raphael Itzykson et al.
BLOOD (2013)
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Raphael Itzykson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease
Leonardo Boiocchi et al.
MODERN PATHOLOGY (2013)
Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis
J. Broseus et al.
LEUKEMIA (2013)
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine
Lionel Ades et al.
LEUKEMIA RESEARCH (2013)
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
Rocco Piazza et al.
NATURE GENETICS (2013)
Somatic SETBP1 mutations in myeloid malignancies
Hideki Makishima et al.
NATURE GENETICS (2013)
Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
Julia E. Maxson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis
Julien Broseus et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Thorsten Braun et al.
BLOOD (2011)
IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia Development
Damien Reynaud et al.
CANCER CELL (2011)
Cytogenetic risk stratification in chronic myelomonocytic leukemia
Esperanza Such et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Incidence and prevalence of myelodysplastic syndromes: Data from the Dusseldorf MDS-registry
Judith Neukirchen et al.
LEUKEMIA RESEARCH (2011)
A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS
John Koreth et al.
BLOOD (2011)
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis
Gerwin Huls et al.
BLOOD (2010)
Morphological evaluation of monocytes and their precursors
Jean E. Goasguen et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome - Comparison with historical experience
Hagop M. Kantarjian et al.
CANCER (2007)
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
Peter Valent et al.
LEUKEMIA RESEARCH (2007)
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features
S. A. Wang et al.
LEUKEMIA (2006)
Risk assessment in chronic myelomonocytic leukemia (CMML)
U Germing et al.
LEUKEMIA & LYMPHOMA (2004)
Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia
F Onida et al.
CANCER (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients
F Onida et al.
BLOOD (2002)
BCR rearrangement-negative chronic myelogenous leukemia revisited
R Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia
JM Hernández et al.
ANNALS OF ONCOLOGY (2000)
分享论文
